(90 days)
No
The summary describes standard image reconstruction and processing techniques for PET/CT systems and does not mention any AI/ML specific terms or capabilities.
No
The device is described as a "diagnostic imaging system" used to "gather metabolic and functional information" for "evaluation, detection, diagnosis, therapeutic planning and therapeutic outcome assessment". These functions are diagnostic or for information gathering related to therapy, not direct therapeutic action.
Yes
The "Intended Use / Indications for Use" section explicitly states that the information gathered by the device "can assist in the evaluation, detection, diagnosis, therapeutic planning and therapeutic outcome assessment of {but not limited to) cancer, cardiovascular disease and brain dysfunction." This clearly indicates its role in diagnosing medical conditions.
No
The device description clearly indicates it is a hardware system combining PET and CT components, not solely software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The described device is an imaging system (PET/CT) that directly images the patient's body using radiopharmaceuticals and X-rays. It does not analyze samples taken from the body.
- Intended Use: The intended use is to gather metabolic and functional information from the distribution of the radiopharmaceutical in the patient body and to function as a CT scanner. This is in vivo imaging, not in vitro testing.
Therefore, while it is a diagnostic device, it falls under the category of medical imaging systems rather than In Vitro Diagnostics.
N/A
Intended Use / Indications for Use
The device is a diagnostic imaging system that combines Positron Emission Tomography (PET) and X-ray Computed Tomography (CT) systems. The CT component produces cross-sectional images of the body by computer reconstruction of x-ray transmission data. The PET component images the distribution of PET radiopharmaceuticals in the patient body. The PET component utilizes CT images for attenuation correction and anatomical reference in the fused PET and CT images.
This device is to be used by a trained health care professional to gather metabolic and functional information from the distribution of the radiopharmaceutical in the body for the assessment of metabolic and physiologic functions. This information can assist in the evaluation, detection, diagnosis, therapeutic planning and therapeutic outcome assessment of (but not limited to) cancer, cardiovascular disease and brain dysfunction. Additionally, this device can be operated independently as a whole body multi-slice CT scanner.
Product codes
JAK, KPS
Device Description
Celesteion, PCA-9000A, is a large bore, TOF, PET-CT system, which combines a high-end CT system with a high-throughput PET system. The high-end CT system is a multi-slice helical CT scanner with a gantry aperture of 900 mm and a maximum scanning field of 700 mm. The high-throughput PET system has a time of flight (TOF) detector with temporal resolution of 450 ps. Celesteion, PCA-9000A, is intended to acquire PET images of any desired region of the whole body and CT images of the same region (to be used for attenuation correction or image fusion), to detect the location of positron emitting radiopharmaceuticals in the body with the obtained images. This device is used to gather the metabolic and functional information from the distribution of radiopharmaceuticals in the body for the assessment of metabolic and physiologic functions. This information can assist research, diagnosis, therapeutic planning, and therapeutic outcome assessment. This device can also function independently as a whole body multi-slice CT scanner.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Positron Emission Tomography (PET), X-ray Computed Tomography (CT)
Anatomical Site
Whole body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained health care professional
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Risk analysis and verification testing conducted through bench testing are included in this submission which demonstrates that the established specifications for the device have been met. CT image quality metrics were performed, utilizing phantoms, which validated that the subject device is substantially equivalent to the predicate device with regard to spatial resolution, CT number and contrast-to-noise ratio and noise properties. Additionally, PET image quality metrics were performed which validated that the subject device met established specifications for spatial resolution, sensitivity, NECR, energy/timing resolution and PET/CT alignment.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1200 Emission computed tomography system.
(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.
0
K.140651
Page 1 of 4
TOSHIBA AMERICA MEDICAL BYBTEMS, INC. 2441 Michelle Drive, Tustin, CA 92780 Phone: (714) 730-5000
JUN 1 1 2014
510(k) SUMMARY
-
- SUBMITTER'S NAME: Toshiba America Medical Systems, Inc.
-
- ADDRESS: 2441 Michelle Drive Tustin, CA 92780-2068
-
- ESTABLISHMENT REGISTRATION: 2020563
-
- CONTACT PERSON: Paul Biggins Director, Regulatory Affairs (714) 730-5000
-
- Date Prepared: March 12, 2014
.
.
-
- TRADE NAME(S): Celesteion, PCA-9000A/2
-
- COMMON NAME: System, X-ray, Computed Tomography System, Positron Emission Tomography
-
- DEVICE CLASSIFICATION: Class II (per 21 CFR §892.1750 and 21 CFR §892.1200)
9. PRODUCT CODE / DESCRIPTION:
JAK - System, Computed Tomography KPS - System, Positron Emission Tomography
10. PERFORMANCE STANDARD:
This device conforms to applicable Performance Standards for lonizing Radiation Emitting Products [21 CFR, Subchapter J, Part 1020]
1
11. PREDICATE DEVICE:
| Product | Marketed by | 510(k) Number | Clearance Date |
|---|---|---|---|
| Aquilion LB Triton, V4.91 | Toshiba America Medical Systems | K123500 | May 2, 2013 |
| Gemini Raptor | Philips Healthcare | K052640 | October 7, 2005 |
12. REASON FOR SUBMISSION:
New device
13. DEVICE DESCRIPTION:
Celesteion, PCA-9000A, is a large bore, TOF, PET-CT system, which combines a high-end CT system with a high-throughput PET system. The high-end CT system is a multi-slice helical CT scanner with a gantry aperture of 900 mm and a maximum scanning field of 700 mm. The high-throughput PET system has a time of flight (TOF) detector with temporal resolution of 450 ps. Celesteion, PCA-9000A, is intended to acquire PET images of any desired region of the whole body and CT images of the same region (to be used for attenuation correction or image fusion), to detect the location of positron emitting radiopharmaceuticals in the body with the obtained images. This device is used to gather the metabolic and functional information from the distribution of radiopharmaceuticals in the body for the assessment of metabolic and physiologic functions. This information can assist research, diagnosis, therapeutic planning, and therapeutic outcome assessment. This device can also function independently as a whole body multi-slice CT scanner.
14. INDICATIONS FOR USE:
The device is a diagnostic imaging system that combines Positron Emission Tomography (PET) and X-ray Computed Tomography (CT) systems. The CT component produces cross-sectional images of the body by computer reconstruction of x-ray transmission data. The PET component images the distribution of PET radiopharmaceuticals in the patient body. The PET component utilizes CT images for attenuation correction and anatomical reference in the fused PET and CT images.
This device is to be used by a trained health care professional to gather metabolic and functional information from the distribution of the radiopharmaceutical in the body for the assessment of metabolic and physiologic functions. This information can assist in the evaluation, detection, diagnosis, therapeutic planning and therapeutic outcome assessment of (but not limited to) cancer, cardiovascular disease and brain dysfunction. Additionally, this device can be operated independently as a whole body multi-slice CT scanner.
15. SUBSTANTIAL EQUIVALENCE:
Celesteion, PCA-9000A/2, is substantially equivalent to the Gemini Raptor which was cleared via Pre-Market Notification 510(k), K052640, marketed by Philips Healthcare as Gemini TF Big Bore.
The CT portion of the Celesteion, PCA-9000A/2, is substantially equivalent to the Aquilion LB Triton system which received 510(k) clearance on May 2, 2013, per K123500. Some minor differences include the use of a moving table base and longer couch top in order to allow scanning in both CT and PET portions and the use of two consoles, one for scanning and one for display, instead of one console that performs both functions. The imaging chain including but not limited to the X-ray tube, detector and data acquisition system of the CT portion is identical to that of the Aquilion LB Triton.
2
The PET portions of the Celesteion and the Gemini Raptor operate on the same principles and basic technologies. Both systems acquire PET images and use their respective CT portions for attenuation correction. Additionally, both systems can combine PET and CT images as fused PET/CT images. The main difference between the systems is that the Celesteion requires a longer imaging duration (user selectable) to obtain equivalent data and image quality as compared to the predicate device.
| Item | Celesteion
PCA-9000A/2 | Gemini Raptor | Aquilion LB Triton,
V4.91 |
|--------------------------------|--------------------------------------------------|------------------------------------------------|--------------------------------------------------|
| 510(k) Number | This submission | K052640 | K123500 |
| PET Specifications | | | |
| Sensitivity (cps/kBq) | $\u2265$ 3.6 | 6.6 | N/A |
| Count rate maximum NECR | 61 $\u00b1$ 10 kcps | 90 | N/A |
| System energy resolution | $\u2264$ 13.7% | 11.7% | N/A |
| System timing resolution | $\u2264$ 450 ps | 495 ps | N/A |
| Scatter fraction (%) | $\u2264$ 42.7 | 26 | N/A |
| Spatial Resolution FWHM at 1cm | $\u2264$ 5.1 | 4.7 | N/A |
| Performance Specifications | | | |
| Scan Regions | Whole body | Whole body | Whole body |
| CT scan FOV | 70 cm | 60 cm | 70 cm |
| Scan System | CT: 360°
continuous rotate/rotate | CT: 360°
continuous rotate/rotate | CT: 360°
continuous rotate/rotate |
| CT Specifications | | | |
| CT Detection System | 16 row
Solid State Detector | 16 row
Solid State Detector | 16 row
Solid State Detector |
| Output capacity | 72 kW (max) | 60 kW | 72 kW (max) |
| X-ray Tube Voltage | 80, 100, 120 and 135 kV | 90, 120, 140 kVp | 80, 100, 120 and 135 kV |
| X-ray Tube Current | 10 mA to 600 mA | 20-500 mA | 10 mA to 600 mA |
| X-ray Tube Heat Capacity | 7.5 MHU | 8 MHU
(Anode storage capacity) | 7.5 MHU |
| X-ray Tube cooling rate | 1,386 kHU/min (max)
1,008kHU/min (actual) | 1,608 kHU/min (max) | 1,386 kHU/min (max)
1,008kHU/min (actual) |
| Focal Spot Size (IEC) | 0.09mm x 0.8mm (small)
1.6mm x 1.4 mm (large) | 0.5mm x 1.0mm (small)
1.0mm x 1.0mm (large) | 0.09mm x 0.8mm (small)
1.6mm x 1.4 mm (large) |
| Lowest couch height | 475 mm
(includes moving base) | Not available | 312 mm (312 mm) |
| Couch-top stroke | 2390 mm | Not available | 2190 mm (1890 mm) |
A complete comparison table is included in this submission. See below for a brief comparison of the technological characteristics between the subject and the predicate devices:
16. SAFETY:
The device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards. This device is in conformance with the applicable parts of the IEC60601-1, IEC60601-1-2, IEC60601-1-3, IEC60601-1-6, IEC60601-2-28, IEC60601-2-44, IEC60825-1, IEC62304, IEC62366, IEC61223, NEMA PS 3.1-3.18, NEMA XR-25, NEMA XR-26 and NEMA NU2.
3
K140651
Page 4 of 4
Additionally, this device complies with all applicable requirements of the radiation safety performance standards, as outlined in 21 CFR §1010 and §1020.
17. TESTING
Risk analysis and verification testing conducted through bench testing are included in this submission which demonstrates that the established specifications for the device have been met. CT image quality metrics were performed, utilizing phantoms, which validated that the subject device is substantially equivalent to the predicate device with regard to spatial resolution, CT number and contrast-to-noise ratio and noise properties. Additionally, PET image quality metrics were performed which validated that the subject device met established specifications for spatial resolution, sensitivity, NECR, energy/timing resolution and PET/CT alignment.
Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission.
Additionally, testing of the system was conducted in accordance with the applicable standards published by the International Electrotechnical Commission (IEC) for Medical Devices and CT Systems.
18. CONCLUSION
Celesteion, PCA-9000A/2, performs in a manner that is similar to and is intended for the same use as the predicate devices, as indicated in product labeling. Based upon this information, conformance to standards, successful completion of software validation, application of risk management and design controls and the performance data presented in this submission it is concluded that the subject device is substantially equivalent in safety and effectiveness to the predicate devices.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol, with three curved lines representing its wings or body. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" in a circular arrangement.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 11, 2014
Toshiba Medical Systems Corporation % Mr. Paul Biggins Director, Regulatory Affairs Toshiba America Medical Systems, Inc. 2441 Michelle Drive TUSTIN CA 92780
Re: K140651
Trade/Device Name: Celesteion, PCA-9000A/2 Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS Dated: March 12, 2014 Received: March 13, 2014
Dear Mr. Biggins:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's reguirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
ﺮ ﺗ .
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
for
Janine M Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
6
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known)
K140651
Device Name
Celesteion, PCA-9000A/2
Indications for Use (Describe)
The device is a diagnostic imaging system that combines Positron Emission Tomography (PET) and X-ray Computed Tomography (CT) systems. The CT component produces crosssectional images of the body by computer reconstruction of x-ray transmission data. The PET component images the distribution of PBT radiopharmaceuticals in the patient body. The PET component utilizes CT images for attenuation correction and anatomical reference in the fused PET and CT images.
This device is to be used by a trained health care professional to gather metabolic and functional information from the distribution of the radiopharmaceutical in the body for the assessment of metabolic and physiologic functions. This information can assist in the evaluation, detection, diagnosis, therapeutic planning and therapeutic outcome assessment of {but not limited to) cancer, cardiovascular disease and brain dysfunction. Additionally, this device can be operated independently as a whole body multi-slice CT scanner.
Type of Use (Select one or both, as applicable)
كا Prescription Use (Part 21 CFR 801 Subpart D)
ال Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Sm.7)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Orug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (1/14)
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.